Clinical trials: Influenza Viruses
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational…
- Trial name
- NCT03282240
- Testing
- QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
- Where
- 36 sites in United States
- Volunteers
- 2,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Adults
A Study to Learn About mRNA Vaccines Against Influenza in Adults
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza…
- Trial name
- NCT07431853
- Testing
- Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3
- Where
- 15 sites in United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT06779981
- Testing
- Nasopharyngeal swabs
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
- Trial name
- NCT03232567
- Testing
- NasoVAX
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Interpandemic Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Trial for annual approval of interpandemic influenza vaccines
- Trial name
- NCT00734734
- Testing
- Seasonal Influenza Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group.
- Trial name
- NCT01959945
- Testing
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Swine-Origin Influenza A H1N1 Virus
Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects
This is to evaluate immunogenicity based on EMEA/CHMP criteria, and safety \& tolerability of cell-derived A/H1N1 influenza HA vaccine in healthy Japanese elderly subjects.
- Trial name
- NCT01069367
- Testing
- Emulsion, Cell Culture-based, influenza HA vaccine H1N1
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Orthomyxoviridae Infections
A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine
This study is designed to generate clinical data as outlined in the Note for Guidance on harmonization requirements for influenza vaccine marketing authorization by the European Medicines Agency.
- Trial name
- NCT00343681
- Testing
- Inactivated influenza vaccine (split virion)
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting…
- Trial name
- CAPSTONE 2 (NCT02949011)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 2,184 people
- Sponsor
- Shionogi
Orthomyxoviridae Infections, Influenza
Immunogenicity Study of the Influenza Vaccine in Adults
All marketed influenza vaccines are injected by the intramuscular (IM) route. This study will test whether an influenza vaccine is effective when injected by a route other than into the muscle.
- Trial name
- NCT00258934
- Testing
- Inactivated, split-virion influenza vaccine, Inactivated, split-virion, influenza virus
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
DTaP-HB-PRP~T combined vaccine is being developed in order to comply with expanding programs for immunization in infancy, while offering the benefit of a reduced number of injections, and potentially of an increased acceptance.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00514709
- Testing
- DTaP-HB PRP~T Combined Vaccine, DTaP-HB-PRP~T vaccine, Oral Polio Vaccine
- Where
- 7 sites in Philippines
- Volunteers
- 1,843 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Severe Influenza
Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms
This is a multicenter, randomized, open Label, add-on study.
- Trial name
- NCT03947411
- Testing
- Oseltamivir Phosphate, Xiyanping injection+Oseltamivir Phosphate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Bird Flu, Influenza
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo.
- Trial name
- NCT01006798
- Testing
- Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
- Where
- 4 sites in United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
SARS-CoV2 Infection, Influenza A
Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of: 1. ClariLight Influenza A/B \& SARS-CoV-2 test kits and 2.
- Conditions
- SARS-CoV2 Infection, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT06175611
- Testing
- COVID-19/Flu A/Flu B/RSV Test Kit
- Where
- 3 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- EDAN Instruments Inc.
Common Cold
Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold
The purpose of the study will be to assess the efficacy and safety of XIGO administered orally, three times a day, compared with placebo in patients with the common cold.
- Trial name
- NCT01092039
- Testing
- lactoferrin, L-Glutamine and beta-glucans
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Xigo Health LLC
Common Cold, Acute Respiratory Infection
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infection.
- Conditions
- Common Cold, Acute Respiratory Infection, Influenza, Human
- Trial name
- NCT05273619
- Testing
- XC8, film-coated tablets, 10 mg
- Where
- 6 sites in Russia
- Volunteers
- 250 people
- Sponsor
- Valenta Pharm JSC
Influenza, Human
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza…
- Trial name
- NCT01390792
- Testing
- Zanamivir hydrate
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Virus Diseases, RNA Virus Infections
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
A phase I/II trial conducted in a single centre, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a single intramuscular injection of plant-based…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT01991587
- Testing
- Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with Fluarix™
- Trial name
- NCT00377611
- Testing
- Fluarix™
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 3,054 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.